Nemaura Medical, Inc. (NMRD) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

500

Shareholding (Dec 2023)

FII

0.09%

Held by 4 FIIs

DII

99.02%

Held by 1 DIIs

Promoter

0.00%

Who are in the management team of Nemaura Medical, Inc.?

22-Jun-2025

As of March 2022, Nemaura Medical, Inc.'s management team includes Dr. Dewan Chowdhury as Chairman, President, and CEO, and Mr. Bashir Timol as Director and Chief Business Officer, along with independent directors Timothy Johnson, Thomas Moore, and Salim Natha.

Is Nemaura Medical, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Nemaura Medical, Inc. to determine a bullish or bearish outlook.

Is Nemaura Medical, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Nemaura Medical, Inc. is considered attractive and undervalued, with a P/E ratio of 15.2 and a P/B ratio of 1.8, significantly lower than peers like Dexcom and Abbott, while also outperforming the Sensex.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.09

Return on Equity

82.66%

Price to Book

-0.00

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2023)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

100.0%

6 Months

100.0%

1 Year

0.0%

2 Years

-99.91%

3 Years

-99.99%

4 Years

-100.0%

5 Years

-99.99%

Nemaura Medical, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-42.00%

EBIT Growth (5y)

-9.91%

EBIT to Interest (avg)

-2.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.36%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-0.00

EV to EBIT

-2.34

EV to EBITDA

-2.48

EV to Capital Employed

11.62

EV to Sales

19.51

PEG Ratio

Dividend Yield

ROCE (Latest)

-495.75%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (0.89%)

Foreign Institutions

Held by 4 Foreign Institutions (0.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -83.33% vs 53.85% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "-1.90",
          "chgp": "21.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "0.80",
          "chgp": "137.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.30",
          "val2": "1.70",
          "chgp": "-23.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-1.20",
          "chgp": "-83.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is -80.00% vs 0.00% in Mar 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -1.44% vs -120.63% in Mar 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-7.30",
          "chgp": "-8.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.40",
          "val2": "6.70",
          "chgp": "-4.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.10",
          "val2": "-13.90",
          "chgp": "-1.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-108,037.80%",
          "val2": "-15,023.50%",
          "chgp": "-9,301.43%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Dec'23

Sep'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.50

-1.90

21.05%

Interest

1.90

0.80

137.50%

Exceptional Items

1.30

1.70

-23.53%

Consolidate Net Profit

-2.20

-1.20

-83.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Sep 2023

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is -83.33% vs 53.85% in Sep 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'23

Mar'23

Mar'22

Change(%)

Net Sales

0.10

0.50

-80.00%

Operating Profit (PBDIT) excl Other Income

-7.90

-7.30

-8.22%

Interest

6.40

6.70

-4.48%

Exceptional Items

0.60

0.00

Consolidate Net Profit

-14.10

-13.90

-1.44%

Operating Profit Margin (Excl OI)

-108,037.80%

-15,023.50%

-9,301.43%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2023 is -80.00% vs 0.00% in Mar 2022

Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -1.44% vs -120.63% in Mar 2022

All Annual Results

Company CV

About Nemaura Medical, Inc.

Nemaura Medical, Inc.

Pharmaceuticals & Biotechnology

Nemaura Medical, Inc. is a holding company. The Company, through its subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. SugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five-minute intervals via a mobile app. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s subsidiaries include Region Green Limited.

Company Coordinates

Company Details

57 W 57th St , NEW YORK NY : 10019-2802

Tel: 44 1509 222912

http://www.nemauramedical.com/

Registrar Details

Nemaura Medical, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

Who are in the management team of Nemaura Medical, Inc.?

Watch in Real-Time

Is Nemaura Medical, Inc. technically bullish or bearish?

Is Nemaura Medical, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ

Annual Results Snapshot (Consolidated) - Mar'23

About Nemaura Medical, Inc.

Company Coordinates